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Abstract 
Background: In the context of malaria elimination/eradication, drugs that are effective against the different develop‑
mental stages of the parasite are highly desirable. The oldest synthetic anti‑malarial drug, the thiazine dye methylene 
blue (MB), is known for its activity against Plasmodium blood stages, including gametocytes. The aim of the present 
study was to investigate a possible effect of MB against malaria parasite liver stages.
Methods: MB activity was investigated using both in vitro and in vivo models. In vitro assays consisted of testing MB 
activity on Plasmodium falciparum, Plasmodium cynomolgi and Plasmodium yoelii parasites in human, simian or murine 
primary hepatocytes, respectively. MB in vivo activity was evaluated using intravital imaging in BALB/c mice infected 
with a transgenic bioluminescent P. yoelii parasite line. The transmission‑blocking activity of MB was also addressed 
using mosquitoes fed on MB‑treated mice.
Results: MB shows no activity on Plasmodium liver stages, including hypnozoites, in vitro in primary hepatocytes. 
In BALB/c mice, MB has moderate effect on P. yoelii hepatic development but is highly effective against blood stage 
growth. MB is active against gametocytes and abrogates parasite transmission from mice to mosquitoes.
Conclusion: While confirming activity of MB against both sexual and asexual blood stages, the results indicate that 
MB has only little activity on the development of the hepatic stages of malaria parasites.
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Background
Malaria remains a major cause of morbidity and mortal-
ity in many regions of the world [1]. In 2016 the World 
Health Organization estimated a total of 212 million 
cases of malaria, which resulted in 429,000 deaths. Afri-
can populations, particularly children younger than 
5  years old, are the most affected by this disease [2]. 
Human malaria is caused by five different species of 
Plasmodium parasites. Plasmodium falciparum and 
Plasmodium vivax are the most common forms with 
P. falciparum being the deadliest. Due to the ability to 
rapidly develop drug resistance, Plasmodium parasites 
continue to be a major challenge for effective case man-
agement [3, 4]. Malaria parasites consist of several life 
cycle stages that have to be individually targeted to reach 
malaria elimination [5].
Most of the drugs used for the treatment of malaria 
act as erythrocytic stage inhibitors. The ambitious goal 
of malaria elimination, however, requires strategies to 
prevent parasite transmission between the human host 
and the mosquito vector, thus targeting the hepatic 
or the gametocyte developmental stages [6]. To date, 
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primaquine (PQ) is the only approved compound active 
against all stages of Plasmodium development: liver 
stages, including hypnozoites, and blood stages, includ-
ing gametocytes, thereby also blocking parasite trans-
mission to mosquitoes. However, PQ causes haemolytic 
anaemia in moderate to severely glucose-6-phosphate 
dehydrogenase (G6PD)-deficient individuals [7]. Moreo-
ver, recent studies show that PQ is ineffective in people 
with low metabolizing cytochrome P450 2D6 genotypes 
[8]. Attempts to develop a replacement for PQ led to 
tafenoquine, a drug of the same class with partly more 
favourable pharmacokinetics, but which is still deleteri-
ous in patients with G6PD deficiency [9, 10]. PQ was 
initially derived from methylene blue (MB) [11, 12], the 
first synthetic drug ever used against malaria [13]. MB 
is a subversive substrate and specific inhibitor of the P. 
falciparum disulfide reductase. It played a major role in 
malaria treatment before and during World War II [14]. 
In recent years, there was a surge of interest in MB as 
an anti-malarial agent when P. falciparum glutathione 
reductase was identified as a new drug target [15]. 
In vitro MB is active against parasites resistant to stand-
ard drugs [16], and oral MB was used to treat uncompli-
cated malaria in Burkina Faso [17]. A triple combination 
of MB with artesunate and amodiaquine was shown 
to be effective against the gametocytes of P. falciparum 
[18]. Furthermore, these clinical trials in Africa showed 
that effective antiplasmodial doses of MB are safe in both 
adults and children including G6PD-deficient individu-
als [19]. MB appears to be a potentially useful partner 
drug for existing artemisinin-based combination therapy 
(ACT), which is first-line anti-malarial treatment. On the 
contrary to its well-described inhibitory activity on blood 
stages, whether MB is able to interfere with Plasmodium 
liver stages is still an open question. Here, MB’s activity 
was assessed against Plasmodium spp liver stages, includ-
ing hypnozoites, in vitro and in vivo, and its transmission 
blocking activity was analysed in vivo.
Methods
Drugs and chemicals
The chlorure of methylthioninium Proveblue was used 
in this study. It is a MB preparation provided by Provep-
harm; a company specialized in the development of 
pharmaceutical products. Today,  Proveblue® methyl-
ene blue active pharmaceutical ingredient (API) is fully 
compliant with most recent pharmacopoeial standards 
on MB. Proveblue was obtained from Olaf Müller. Fig-
ure 1 shows the chemical structure of the compound. For 
in vitro and in vivo assays MB was dissolved in distilled 
water. Primaquine used in these studies was obtained 
from Sigma-Aldrich, USA. Stock solutions were prepared 
at 10  mg/ml in distilled water. d-Luciferin, provided by 
OZBioscences, a substrate for luciferase was dissolved in 
1× phosphate-buffered saline (PBS) (Gibco) and injected 
intraperitoneally at 100 mg/kg.
Parasites and sporozoites isolation
Three species of Plasmodium were used in this study:
1. Plasmodium falciparum (NF54 strain) sporozo-
ites were obtained from infected salivary glands of 
Anopheles stephensi 14–21  days after an infective 
blood meal (Department of Medical Microbiology, 
Radboud  University Medical Center, Nijmegen, The 
Netherlands).
2. Plasmodium cynomolgi (M strain) sporozoites were 
obtained from infected salivary glands of An. ste-
phensi 14–16  days after an infective blood meal 
(blood infected with P. cynomolgi was obtained from 
Macaca fascicularis, the natural host of P. cynomolgi, 
infected with cryopreserved blood stages) (CEA, 
Fontenay aux Roses, France).
3. Plasmodium yoelii (17XNL strain), line express-
ing GFP-Luciferase (GFP-luc) was generated using a 
‘Gene Out Marker Out’ strategy [20].
Infected salivary glands were aseptically removed by 
hand dissection, crushed in a potter and filtered through 
a 40-µm filter for sporozoite isolation (Cell Strainer, BD 
BioSciences, USA). Sporozoites were counted using a dis-
posable Glasstic microscope slide (KOVA, USA).
Mice and mosquitoes
Six to 8  weeks old female BALB/c mice (18–22  g), 
obtained from Janvier (Le Genest-Saint-Isle, France) were 
used. For in  vivo transmission blocking studies with P. 
yoelii, 4–5 days old An. stephensi female mosquitoes were 
used as experimental vectors.
Hepatocytes
Primary human hepatocytes were isolated from liver seg-
ments obtained from adult patients undergoing partial 
hepatectomy (Service de Chirurgie Digestive, hépato-bilio 
pancréatique, Hôpital Pitié Salpêtrière, Paris France). 
Primary simian hepatocytes were isolated from liver 
Fig. 1 Chemical structures of a methylene blue (MB) and b 
primaquine (PQ)
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segments collected from healthy Macaca fascicularis 
from CEA, Fontenay aux Roses, France or ICM, Hôpital 
Pitié Salpêtrière, Paris France. Primary murine hepato-
cytes were isolated from liver segments collected from 
BALB/c mouse.
All hepatocytes were isolated using collagenase perfu-
sion as previously described [21, 22]. Simian hepatocytes 
were immediately cryopreserved with a Nicool-Freezal 
(Air liquide Santé, Marne la vallée) and then used when 
needed after fast thawing at 37  °C. Human and murine 
hepatocytes were used in fresh cultures. Cells were 
seeded in 96-well plates (Falcon by Becton–Dickinson 
Labware Europe, France) coated with collagen I (BD 
Biosience, USA), at a density of 80,000 cells per well. 
Human, simian and murine hepatocytes were maintained 
at 37  °C in 5%  CO2 in William medium (Gibco) sup-
plemented with 10% of fetal bovine serum (FBS, Fetal-
Clone, Hyclone), 1% penicillin–streptomycin (Gibco), 
5 × 10−3  g/l insulin (Sigma Aldrich, USA) and 5 × 10−5 
hydrocortisone (Upjohn Laboratories SERB, France) until 
infection with sporozoites. For human hepatocytes, the 
complete medium was supplemented with 2% dimethyl 
sulfoxide (DMSO, Sigma- Aldrich, USA) until infection.
Assessment of liver stage development in vitro
Hepatocytes were seeded into collagen-coated black 
96-wells plates and maintained at 37  °C in 5%  CO2 in 
a complete medium. On the day of infection, 3 × 104 
sporozoites of P. falciparum, P. cynomolgi or P. yoe-
lii resuspended in complete medium were added to the 
respective host cell cultures (human, simian or murine). 
The infected culture plates were centrifuged for 10  min 
at 900g allowing fast parasite sedimentation and further 
incubated for 3  h at 37  °C/5%  CO2 allowing parasites 
invasion into the hepatocytes. Serial dilution of the tested 
drugs, MB and PQ were added to the cultures. Culture 
medium containing the appropriate drug concentration 
was changed daily and cells were fixed 48 h post infection 
(pi) for P. yoelii, 6 days pi for P. falciparum or 8 days pi for 
P. cynomolgi.
Parasite counting and schizont size determination using 
high‑content imaging
The number, size and shape of the parasites were deter-
mined using a CellInsight High Content Screening 
platform equipped with the Studio HCS software (Ther-
moFisher Scientific). Parasite immunostaining was 
done using a α-Plasmodium HSP70 antibody raised in 
mice and a secondary anti-mouse antibody coupled to 
AlexaFluor 488 [23]. Host cell and parasite nuclei were 
labelled with 4′,6-diamidino-2-phenylindole (DAPI). 
Thirty-seven images, representing more than 95% of 
the total bottom surface area of a culture well in 96-well 
plates, were captured for analysis. The custom script 
used for counting and measuring parasites first required 
identification of the objects on the basis of a fluorescence 
intensity threshold. The object identity was then further 
validated based on size and morphological (shape) cri-
teria. The presence of DAPI-associated fluorescence in 
the selected objects allowed for their final selection and 
rejection of false positives. Inhibitory concentration 50 
 (IC50) value is the drug concentration at which a 50% 
reduction of the exo-erythrocytic forms (EEFs) number 
was observed, as compared to the control cultures.  IC50 
were calculated using ICEstimator software version 1.2 
[24].
The parasite size reduction is calculated on the average 
object area using the total surface area of each selected 
object (µm2). Cell confluence for primary hepatocytes 
was measured by counting the absolute number of host 
cell nuclei using a script that first requires identifica-
tion of the objects on the basis of the DAPI fluorescence 
intensity threshold and then involved a validation step 
based on size and morphological (shape) criteria. The 
objects on the edge of the pictures were excluded. The 
toxic concentration 50  (TC50) value was determined as 
the drug concentration at which a 50% reduction of the 
cell confluence was estimated. With  IC50 and  TC50, thera-
peutic index (TI) was calculated  (TC50/IC50).
Assessment of liver stage in vivo development
Five mice per treatment group were used. Experimen-
tal groups were treated with MB at 50 and 100  mg/kg 
by intra-peritoneal (ip) injection. Untreated infected 
mice, non-infected mice (infection controls) as well as 
PQ-treated (50  mg/kg) mice (control drug) were also 
included. The drugs were administrated on days − 1, 0, 
+1, and mice were challenged on day 0 by retro-orbital 
injection of P. yoelii (GFP-luc strain) sporozoites (10,000 
per mouse). In  vivo imaging was performed 44  h post-
infection to assess liver stage development. When para-
sites were detected in the liver, treatment was continued 
until day 5 to assess blood stage activity. On day 4 and 
6 pi, in vivo imaging and GIEMSA-stained blood smears 
were performed to monitor blood stage development 
using methods described previously [25]. IVIS Spectrum 
(Caliper Life Science, Hanover, MD, USA) was used to 
measure luciferase activity. Prior to analysis the mice 
were injected ip with D-luciferin (100  mg/kg), anesthe-
tized with isoflurane and imaged 10  min post-injection. 
Images were analysed using the living Image 3.0 software 
(Capiler Life Science, Hanover, MD, USA). For blood 
stage assessment, luminescence (total flux photons/sec-
onde) and Giemsa-stained blood smears were done on 
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days 3, 4 and 6 pi to evaluate the blood stage prepatent 
period in mice after sporozoite inoculation.
In vivo blood stage and transmission blocking activity 
assays
Mice were infected by ip inoculation of  107 erythrocytes 
parasitized with GFP-luc P. yoelii and separated in two 
groups. The first group was treated from day 0 to day 3. 
For the second group, treatment was initiated 4 days after 
the infection, 2 h before mosquito feeding [26]. For each 
compound (Control: PBS, MB 50  mg/kg) and for each 
treatment protocol, mice were randomly separated into 
groups of five animals. At day 3, the presence of game-
tocytes was checked by microscopic analysis of Giemsa-
stained blood films and their functionality was assessed 
using microgamete exflagellation assay. Mice were anes-
thetized and placed according to the treatment on the 
top of individual cages containing 100 glucose-starved 
An. stephensi female mosquitoes, which were allowed to 
feed for 1 h. Unfed mosquitoes were removed from the 
cage. Seven days after the blood meal, 30–40 mosquitoes 
were dissected and their midguts examined under light 
microscope (400×) to assess oocyst presence. Two weeks 
after the blood meal, salivary glands of 30–40 mosquitoes 
per group were dissected to determine the average num-
ber of sporozoites per mosquito in each group. Inhibition 
activity was determined by determining the percentage 
of oocyste-positive mosquitoes (infection rate), the mean 
number of oocysts per mosquito (oocyst burden) and the 
mean number of sporozoites per mosquito.
Statistical analysis
Excel 2007 spreadsheet (Microsoft office) and GraphPad 
Prism 6 statistical Software (GraphPad. Software, San 
Diego, CA, USA) were used for data analysis. All values 
were expressed as means and standard deviations (SD). 
A p value of 0.05 or less was considered as statistically 
significant.
Results
In vitro activity against Plasmodium liver stages
MB was tested at concentrations ranging from 0.02 to 
100 µM on primary murine, human and simian hepato-
cytes infected, respectively, with P. yoelii, P. falciparum 
and P. cynomolgi. MB and PQ (Fig.  1) cytotoxicity was 
evaluated by assessing cell confluence and number of 
DAPI-positive hepatocytes after drug treatment and anti-
malarial activity was evaluated by counting EEFs (Figs. 2 
and 3).
As shown in Table 1, MB had no effect  (IC50 > 100 µM) 
on P. falciparum, P. cynomolgi and P. yoelii liver stages 
including P. cynomolgi hypnozoites (Fig.  2c). The cor-
responding TI (TI = TC50/IC50) in these primary 
hepatocytes  (TC50 > 100  µM) was very low (TI = 1). As 
expected, PQ was highly active on P.  falciparum and P. 
cynomolgi liver stages with  IC50 of 0.6 µM in human cells 
and 2.72 µM in simian cells. The TI of PQ was, respec-
tively, 66.5 in human hepatocytes  (TC50 39.93 ± 2.29 µM) 
and 14.22 in simian hepatocytes  (TC50 38.7 ± 2.98  µM). 
In addition, MB had limited effect on parasite develop-
ment, as evaluated by measuring parasite size (Table 1). 
At 11 µM, MB induced a 10% reduction of P. falciparum 
and P. cynomolgi parasite area.
In vivo activity against Plasmodium yoelii liver stage
Two groups of BALB/c mice were treated with MB at 
50 and 100 mg/kg or PQ at a concentration of 50 mg/kg 
one day prior the infection, the day of infection and 1 day 
post-infection. PQ (50  mg/kg) served as a positive con-
trol. The results illustrate that MB was unable to prevent 
parasite blood stage development (Fig. 4a). Mice treated 
with PQ were free of parasites throughout the infec-
tion experiment (Fig. 4a). Mean luminescence (photons/
sec) values collected from liver location of mice were 
2.11 × 107 (± 6.39 × 106) for untreated control group, 
1.66 × 107 (± 3.07 × 106) for MB 50  mg/kg and 2.97x106 
(± 2.00 × 106) for MB 100 mg/kg at 44 h pi (Fig. 4b). Plas-
modium yoelii liver stage inhibition was, respectively, 
21.43 and 85.9% for MB at 50 and 100  mg/kg. At days 
3 and 4 post-infection, the luminescence signal spread 
in the entire body due to parasite dissemination in the 
blood circulation. When the growth of parasites is com-
pared between day 2 and day 4, the signal increased five 
times in the control group whereas in the groups treated 
with MB there was a reduction of the luminescence signal 
(Fig.  4b). In order to validate these results, mean lumi-
nescence was correlated with blood parasitaemia based 
on blood smears microscopic examination on days 3, 4 
and 6 pi. Compared to untreated controls, blood parasi-
taemia was strongly diminished after treatment of mice 
on days 4 and 6 with 50 and 100 mg/kg MB. The protocol 
using 100  mg/kg showed a slightly increased effective-
ness (Fig. 4c). These results show that MB has a moderate 
effect on liver stages, albeit at a level unable to prevent 
blood stage development. Conversely, MB strongly inhib-
its blood stage growth in vivo.
In vivo transmission blocking assays
In order to analyse the ability of MB to inhibit para-
site transmission to mosquitoes, An. stephensi mos-
quitoes were fed on P. yoelii-infected BALB/c mice 
with or without MB treatment. The mean number of 
oocysts per mosquito (oocyst burden) and the mean 
number of sporozoites per mosquito were dramatically 
decreased showing that MB efficiently reduces transmis-
sion (Fig.  5). Table  2 shows the mean parasitaemia and 
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gametocytaemia before a mosquito’s blood meal. Mice 
treated from day 0 to day 3 showed a remarkable reduc-
tion of parasitaemia of nearly 79% as well as a reduction 
of gametocytaemia of 100% compared to the control 
group. These results clearly show that MB can inhibit 
parasite transmission by eliminating gametocytes. Treat-
ment applied 2 h before mosquito feeding had no effect 
on the gametocyte rate in the mice, as observed on blood 
smears, but induced a drastic reduction of both the mos-
quito infection rate and the number of oocysts in infected 
mosquito midguts dissected 1 week post infection (mean 
number of 128 oocysts per infected mosquito in the con-
trol group compared to 8 oocysts in the treated group). 
As expected, this decrease in the oocyst number led to 
a strong reduction in sporozoite numbers in salivary 
glands 2 weeks post mosquito blood meal (Fig. 5b). From 
this last experiment, the conclusion was that a short-
term exposure to MB is sufficient to prevent Plasmodium 
transmission to An. stephensi mosquitoes. 
Discussion
Most currently available anti-malarial drugs primarily 
target the disease-causing parasite stages in the human 
blood system. However, to eradicate malaria, new drugs 
that block transmission of the parasite between the 
Fig. 2 Activity of methylene blue (MB) and primaquine (PQ) in primary hepatocytes. a Activity of MB against liver stage of P. falciparum in human 
hepatocytes, (N 221 ± 50). b Activity of PQ against liver stage of P. falciparum in human hepatocytes, (N 301 ± 55). c Activity of MB against liver stage 
of P. cynomolgi in simian hepatocytes, (N 176 ± 22). d Activity of PQ against liver stage of P. cynomolgi in simian hepatocytes, (N 237 ± 4). Activity 
(infection scale, black bars = EEFs, grey bars = hypnozoites) and toxicity to host cells (cell confluency scale and red circles). Data are mean ± SD of 
triplicate measurements from a single representative experiment. N number of parasites in control
Fig. 3 Activity of methylene blue against Plasmodium yoelii in 
murine primary hepatocytes. (N 34 ± 6). Activity (infection scale, black 
bars = EEFs, grey bars = hypnozoites) and toxicity to host cells (cell 
confluency scale and red circles). Data are mean ± SD of triplicate 
measurements from a single representative experiment
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human host and the mosquito vector, and eliminate 
the various stages of the parasite during its cycle in the 
human body, are needed. It is surprising that few stud-
ies [27], to date, have examined drug activity against liver, 
sexual blood and mosquito stages of the malaria parasite 
at the same time. In this study, PVB activity was assessed 
on these different parasite stages. PVB is a MB prepara-
tion that complies with the European Pharmacopoeia, 
contains limited organic impurities and heavy metals 
of recognized toxicity, and has previously been demon-
strated to possess anti-malarial activity on asexual and 
sexual blood stages. In vitro experiments confirmed PVB 
anti-malarial potency against the blood stage of 23 P. fal-
ciparum strains that were resistant to various anti-malar-
ial drugs [16]. In combination with mefloquine, quinine 
and dihydroartemisinin, PVB showed synergistic effects 
in  vitro against 9 well-established P. falciparum strains 
[28, 29]. Ex  vivo experiments on 19 samples isolated 
from patients showed  IC50 for PVB ranging from 0.88 to 
40.2 nM with a mean of 5.3 nM [30]. PVB treatment at 
1–10 mg/kg for 5 days significantly reduced or prevented 
cerebral malaria in mice [31–33]. In humans, several clin-
ical trials conducted in Burkina Faso showed that oral MB 
was safe and effective in the treatment of uncomplicated 
falciparum malaria when combined with other anti-
malarials [17, 18, 34–36]. Another study reported mod-
erate curative activity with MB monotherapy, illustrating 
the need for this slow-acting drug to be combined with 
fast-acting anti-malarials [37]. Another advantage of MB 
is that it has gametocytocidal properties and can reduce 
the transmission of P. falciparum. In fact, MB interferes 
in vitro on gametocyte development at all stages and can 
block transmission through clearance of stage V game-
tocytes [38]. Previous clinical observations showed that 
MB reduced gametocyte carriage rate in treated patients 
[18, 39]. So far no published study has analysed the activ-
ity of MB on the hepatic stage of Plasmodium parasites. 
Here, several established models of malaria liver stages 
were used to evaluate the effectiveness of PVB. The P. 
yoelii murine model has two main interests, it allows: (1) 
a quick and ‘easy’ in vitro screening of the molecules; and, 
(2) to draw a parallel between in vitro and in vivo experi-
ments. Murine Plasmodium species are commonly used 
to study the liver stage of infection in mice and in vitro, 
yet it is not clear how well these models reflect P. falci-
parum infections in humans. Then, two in vitro models: 
P. falciparum and P. cynomolgi were used to validate the 
results with P. yoelii model. The P. falciparum experi-
ments provide direct data on pharmacodynamic effects 
against the liver and blood stages of this most impor-
tant human malaria parasite. The P. cynomolgi system is 
being used as a model for P. vivax and replicates its capa-
bility to produce hypnozoites. This P. cynomolgi model 
has been used for decades to identify radical curative 
compounds against P. vivax [40, 41]. In all these mod-
els, PVB showed no significant activity on Plasmodium 
liver stage infection in vitro. Interestingly, MB could par-
tially reduce the parasite burden in the liver of P. yoelii-
infected mice; however this effect was observed only at 
the highest doses and was not sufficient to prevent tran-
sition to a blood stage infection. To date, there is only a 
limited number of therapeutics capable of eliminating 
Plasmodium liver stages [42, 43]. Whereas PQ, as well 
as tafenoquine, and atovaquone actively eliminate divid-
ing Plasmodium liver stages, only PQ has a pronounced 
effect on the hypnozoites [22]. However, because of its 
potential to cause life-threatening acute intravascular 
haemolysis in individuals with severe G6PD deficiency, 
PQ cannot be widely used [44]. Thus, the development 
of new compounds with hypnozoitocidal activity suitable 
for mass administration has become a priority in the cur-
rent drive to eliminate malaria.
In the present study, MB shows low or no activity 
in vitro in primary hepatocytes while PQ is very effective. 
Next, in  vivo experiments were performed to evaluate 
the effect of MB on hepatic and blood stages develop-
ment. In  vivo imaging of Plasmodium growth was used 
to measure the specific inhibition of parasite hepatic 
Table 1 Comparative inhibitory activities of  Proveblue and  primaquine on  Plasmodium yoelii, Plasmodium falciparum 
and Plasmodium cynomolgi 
MH mouse hepatocytes; HH human hepatocytes; SH simian hepatocytes; TI therapeutic index:  TC50/IC50, ND not determined
a [51]
Drugs Methylene blue Primaquine
Parasites IC50 (µM) TI Size reduction at 11 µM 
(%)
IC50 (µM) TI Size 
reduction 
at 11 µM (%)
P. yoelii (MH) >  100 1 10 0.64 ± 0.1a 110a ND
P. falciparum (HH) >  100 1 10 0.6 ± 0.06 66.5 100
P. cynomolgi (SH) >  100 1 10 2.72 ± 0.34 14.22 70
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stage development and its consequences on blood stage 
spreading [45, 46]. All control mice used showed a strong 
luminescence signal at 44  h, as well as on day 3 and 4 
post-infection while luminescence signal was abrogated 
in animals treated with PQ (50 mg/kg). In these experi-
ments, while MB was not able to prevent spreading of the 
parasites into the central circulation (Fig.  4), an inhibi-
tory effect was observed using the high dose of 100 mg/
kg, demonstrating once again that to prevent erythro-
cytic infection, hepatic inhibition has to be close to 100%. 
These results have to be considered with those obtained 
by Garavito in his thesis [47]. Studying the pharmaco-
logical effects of MB, he observed a slight delay in the 
appearance of the erythrocytic infection.
Finally, the activity of MB against P. yoelii blood 
stages was confirmed and its transmission blocking 
Fig. 4 In vivo anti‑malarial activity of methylene blue against liver and blood stage. Mice were infected with 10,000 sporozoites. MB (50 and 
100 mg/kg) and PQ (50 mg/kg) were administreted on day − 1, 0 and 1 to monitor activity against liver stage on day 2 and on day 3 and 4 to 
monitor blood stage activity. a Representative in vivo images (IVIS) of luminescence show in the liver of live Balb/C mice at different time points. 
Rainbow images show the relative levels of luminescence ranging from low (blue), to medium (green), to high (yellow/red). b Mean luminescence 
levels (photons/sec) of each group at day 2, 3 and 4; (**p = 0.0031, ***p = 0.0001, ****p < 0.0001). c Blood stage patency was monitored in mice by 
Giemsa‑stained blood smears on day 3, 4 and 6. The results are expressed as the mean ± standard errors of the mean of 4 or 5 measurements
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activity too. Indeed, parasitaemia was reduced by 80% 
in mice infected with  107 P. yoelii infected red blood 
cells when MB (50  mg/kg) was applied from day 0 to 
day 3 (Table 2), leading to the disappearance of game-
tocytes from the circulation. These results are in agree-
ment with preliminary clinical data showing a complete 
elimination of asexual stages and gametocytes in the 
blood stream of MB-treated malaria patients [18, 39]. 
Even more interesting, MB considerably decreased the 
prevalence of infected mosquitoes when the treatment 
was administrated 2  h before feeding. These observa-
tions are in line with results on gametocyte develop-
ment in the P. falciparum model [38].
Why is MB little effective at the hepatic level while 
it is very active on blood stage and gametocytes? A 
failure of its uptake into the infected host cell? The 
typical example is fosmidomycin, an antibiotic with 
relatively rapid action against asexual blood stages. Pre-
vious work established that fosmidomycin is efficiently 
transported into P. falciparum-infected erythrocytes 
through parasite-induced new permeability pathways. 
In contrast, Plasmodium berghei liver-stage parasites 
were shown to be resistant to fosmidomycin, presum-
ably due to the inability of this compound to enter 
hepatocytes [48–50].
Another explanation could be that, similarly to 
PQ [8], MB would require metabolization by hepatic 
cytochromes to become active. This would imply that the 
effect of MB on Plasmodium blood stages is due to one or 
more active metabolites. This is the case of several drugs 
that are considered prodrugs. For instance, proguanil is 
a prodrug and its cyclisation by cytochrome P450 into 
pharmacologically active triazine metabolite (cyclogua-
nil) inhibits plasmodial dihydrofolate reductase. This 
biotransformation is catalyzed by CYP2C19 and many 
anti-malarial lead compounds are being designed and 
synthesized to exploit this pathway [51].
Conclusion
This study confirms that MB, a precursor of PQ, belongs 
to the large group of anti-malarial compounds active 
against malaria blood-stage parasites. Moreover it has an 
effect on gametocytes, thus preventing transmission to 
mosquitoes. Unfortunately, MB, in the formulation used 
in endemic areas, is likely inactive against Plasmodium 
hepatic stage.
Abbreviations
DAPI: 4′,6‑Diamidino‑2‑phénylindole; MB: methylene blue; PQ: primaquine; 
PVB: Proveblue; G6PD: glucose‑6 phosphate dehydrogenase; TI: therapeutic 
Fig. 5 Impact of methylene blue 50 mg/kg on sporogonic development. a Number of oocysts per midgut. Each point represents the oocyst 
number from an individual mosquito. Oocysts density in MB groups significantly different with the untreated group (***p < 0.0001). b Average of 
sporozoites extracted from salivary glands of mosquitoes (Total of sporozoites/number of mosquitoes). (**p < 0.0016)
Table 2 Parasitaemia and gametocytaemia before feeding and prevalence of infected mosquitoes in each group
The results are expressed as mean ± standard errors. The result shown is representative of 1 assay of the 2 independent assays performed
Untreated MB 2H MB D0–D3
Parasitaemia (%) 0.95 ± 0.39 1.36 ± 0.18 0.2 ± 0.02
Gametocytaemia (%) 0.08 ± 0.02 0.097 ± 0.06 0
Prevalence infected mosquitoes (%) 82.28 (29/35) 65.71 (23/35) 0 (0/35)
Oocytes mean per infected mosquitoes 128 8 0
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index; IC50: drug concentration that kill 50% of parasites; TC50: drug concentra‑
tion that kill 50% of the hepatocytes; EEFs: exo‑erythrocytic forms.
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